Menu
← Oncology Approval Tracker
FDA DECISION ·
Lanreotide Acetate Injection
lanreotide acetate · Cipla
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with carcinoid syndrome, to reduce the need for short-acting somatostatin analog rescue therapy.
LAMPGEN ANALYSIS
Why it matters
The separate lanreotide product gained a symptom-control indication, distinct from an antitumor progression endpoint.
What research teams should watch
Record rescue medication use and symptom burden so treatment changes can be interpreted alongside the injection schedule.
PRIMARY RECORDS